Real-time Euronext Paris 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Biom'Up -.--% -.--%
Sales 2017 1.77M 1.89M Sales 2018 1.18M 1.26M Capitalization 65.86M 70.47M
Net income 2017 -31M -33.17M Net income 2018 -40M -42.8M EV / Sales 2017 72.3 x
Net cash position 2017 21.49M 23M Net cash position 2018 1.81M 1.94M EV / Sales 2018 54.5 x
P/E ratio 2017
-2.48 x
P/E ratio 2018
-1.43 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 93.35%
More Fundamentals * Assessed data
Dynamic Chart
Biom’Up Appoints Stéphanie Boileau-Canu as Chief Financial Officer CI
Biom’Up Expands Management Team CI
Biom’Up Announces Plan to Sell Assets to Athyrium CI
Biom'up Announces the Approval of HEMOBLAST (Tm) Bellows and Its Laparoscopic Applicator in Australia; Reaffirms Revenue Guidance for 2019 CI
Biom'Up S.A. Provides Revenue Guidance for the First Nine Months and Full-Year of 2019 CI
Biom'Up S.A. Announces Executive Changes CI
Biom'up S.A. Announces Publication of Clinical Case Studies Highlighting the Use of the Company's Lead Novel Hemostatic Product, Hemoblast Bellows in Cardiovascular Procedures CI
Biom'Up S.A Announces Unaudited Sales Results for the First Half Ended June 30, 2019; Reiterates Revenue Guidance for the Full-Year of 2019 CI
Biom'up S.A. Announces Change in Leadership Position CI
Biom'up Announces Consolidated Earnings Results for the Year of 2018 CI
Biom'up S.A. Announces U.S. Food and Drug Administration Approves the IDE (Investigational Device Exemption) Application for HEMOSNOW CI
Biom'up Signs of an Exclusive Distribution Agreement for HEMOBLAST(TM) Bellows in Australia with Life Healthcare Distribution CI
Biom’Up Appoints George Makhoul as Chief Commercial Officer CI
Biom'Up S.A. Announces the Publication of Scientific and Clinical Data with its Product HEMOBLAST Bellows CI
Biom’Up Granted FDA Approval for Its HEMOBLAST™ Bellows Laparoscopic Applicator CI
More news
Managers TitleAgeSince
Chief Executive Officer - 19-12-20
Director of Finance/CFO 56 -
Compliance Officer - 16-02-29
Members of the board TitleAgeSince
Director/Board Member 50 18-01-29
Director/Board Member 56 -
Director/Board Member - 18-01-29
More insiders
Biom Up SA is a France-based company engaged in the design, development and production of medical devices. The products of the Company are based on biopolymers such as collagen. Biom Up SA markets two lines of products: Cova line (including Cova ORTHO, Cova CARD and Cova MAX, among others), which is a membrane for adhesion prevention and guided healing, and MatriBONE, which is a bone regeneration matrix with haemostatic, absorbable and osteoconductive properties. MatriBONE is used in orthopedic and maxillofacial surgery for the filling of bone defects whether it is from surgical, traumatic or pathological origin. The Company also designs other products, such as dental surgery products and several collagen types, which are developed and manufactured for the Company's partners.
More about the company